Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant

References

• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397–404.
   PubMed Web of Science ®Google Scholar
• Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 2008;97:1329–1349.
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60.
   PubMed Web of Science ®Google Scholar
• Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res 2004;21:1167–1176.
   PubMed Web of Science ®Google Scholar
• Moore MD, Wildfong PLD. Aqueous solubility enhancement through engineering of binary solid composites: Pharmaceutical applications. J Pharm Innovat 2009;4:36–49.
   Web of Science ®Google Scholar
• Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm 2008;5:1003–1019.
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009;26:139–151.
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Rumondor AC, Nivens DE, Kestur US, Stanciu L, Taylor LS. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J Pharm Sci 2010;99:169–185.
   PubMed Web of Science ®Google Scholar
• Chan HK, Grant DJW. Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. Int J Pharm 1989;57:117–124.
   Web of Science ®Google Scholar
• Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 2001;48:91–114.
   PubMed Web of Science ®Google Scholar
• Ranzani LS, J. F, Galimany F, Santanach A, Gomez-Gomar AM, G. C, Galimany F, Gryczke A. Enhanced in vivo absorption of CB-1 antagonist in rats via solid solutions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2011: DOI: 10.3109/03639045.03632010.03535822.
   PubMedGoogle Scholar
• Thybo P, Pedersen BL, Hovgaard L, Holm R, Mullertz A. Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm Dev Technol 2008;13:375–386.
   PubMed Web of Science ®Google Scholar
• Shah J, Vasanti S, Anroop B, Vyas H. Enhancement of dissolution rate of valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: Preparation and in vitro evaluation. J Incl Phenom Macro 2009;63:69–75.
   Web of Science ®Google Scholar
• Fini A, Cavallari C, Ospitali F. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles. Eur J Pharm Biopharm 2008;70:409–420.
   PubMed Web of Science ®Google Scholar
• Thybo P, Kristensen J, Hovgaard L. Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm Dev Technol 2007;12:43–53.
   PubMed Web of Science ®Google Scholar
• Damian F, Blaton N, Desseyn H, Clou K, Augustijns P, Naesens L et al.Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). J Pharm Pharmacol 2001;53:1109–1116.
   PubMed Web of Science ®Google Scholar
• Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 1999;181:143–151.
   PubMed Web of Science ®Google Scholar
• Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997;14:1691–1698.
   PubMed Web of Science ®Google Scholar
• Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int J Pharm 1996;143:59–66.
   Web of Science ®Google Scholar
• Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 2004;21:133–193.
   PubMedGoogle Scholar
• Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm Res 2006;23:1928–1936.
   PubMed Web of Science ®Google Scholar
• Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm 2007;328:119–129.
   PubMed Web of Science ®Google Scholar
• de Waard H, Hinrichs WL, Visser MR, Bologna C, Frijlink HW. Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. Int J Pharm 2008;349:66–73.
   PubMed Web of Science ®Google Scholar
• Sinclair W, Leane M, Clarke G, Dennis A, Tobyn M, Timmins P 2011. Physical Stability and Recrystallization Kinetics of Amorphous Ibipinabant Drug Product by FT-Raman Spectroscopy. J Pharm Sci:In Press. DOI: 10.1002/jps.22658.
   Google Scholar
• Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 2004;47:627–643.
   PubMed Web of Science ®Google Scholar
• Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 2009;370:167–174.
   PubMed Web of Science ®Google Scholar
• Tobyn M, Brown J, Dennis AB, Fakes M, Gao Q, Gamble J et al. Amorphous drug-PVP dispersions: application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J Pharm Sci 2009;98:3456–3468.
   PubMed Web of Science ®Google Scholar
• Jordan MP. 1999. Moisture barrier film coating composition, method, and coated form. In Office USP, editor, ed., US: BPSI Holdings, Inc. US Patent No 5, 885, 617.
   Google Scholar
• Fowler CE, Gracia L, Edwards MI, Brown A, Rees GD. Fluoride penetration from toothpastes into incipient enamel erosive lesions investigated using dynamic secondary ion mass spectrometry. J Clin Dent 2009;20:186–191.
   PubMedGoogle Scholar
• Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 1994;11:471–477.
   PubMed Web of Science ®Google Scholar
• Xie Y, Tao W, Morrison H, Chiu R, Jona J, Fang J et al. Quantitative determination of solid-state forms of a pharmaceutical development compound in drug substance and tablets. Int J Pharm 2008;362:29–36.
   PubMedGoogle Scholar
• Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J et al. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm 2005;59:119–126.
   PubMed Web of Science ®Google Scholar
• Rumondor AC, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res 2009;26:2599–2606.
   PubMed Web of Science ®Google Scholar
• Airaksinen S, Karjalainen M, Kivikero N, Westermarck S, Shevchenko A, Rantanen J. Excipient selection can significantly affect solid-state phase transformation in formula wet granulation. AAPS PharmSciTech 2005; 6:E311–322.
   PubMedGoogle Scholar
• Airaksinen S, Luukkonen P, Jørgensen A, Karjalainen M, Rantanen J, Yliruusi J. Effects of excipients on hydrate formation in wet masses containing theophylline. J Pharm Sci 2003;92:516–528.
   PubMed Web of Science ®Google Scholar
• Ku MS, Dulin W. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. Pharm Dev Technol 2010; 1–18. DOI: 10.3109/10837450.2010.535826.
   PubMedGoogle Scholar
• Hulse WL, Forbes RT, Bonner MC, Getrost M. The characterization and comparison of spray-dried mannitol samples. Drug Dev Ind Pharm 2009;35:712–718.
   PubMed Web of Science ®Google Scholar
• Balani PN, Ng WK, Tan RB, Chan SY. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. J Pharm Sci 2010;99:2462–2474.
   PubMed Web of Science ®Google Scholar
• Schmidt AG, Wartewig S, Picker KM. Potential of carrageenans to protect drugs from polymorphic transformation. Eur J Pharm Biopharm 2003;56:101–110.
   PubMed Web of Science ®Google Scholar
• Dhumal RS, Shimpi SL, Paradkar AR. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers. Acta Pharm 2007;57:287–300.
   PubMedGoogle Scholar
• Colombo I, Grassi G, Grassi M. Drug mechanochemical activation. J Pharm Sci 2009;98:3961–3986.
   PubMed Web of Science ®Google Scholar
• Descamps M, Willart JF, Dudognon E, Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g). J Pharm Sci 2007;96:1398–1407.
   PubMed Web of Science ®Google Scholar
• Randolph Sanders J, Mason PJ, Whiteman M. Digital Fabrication 2005 - Final Program and Proceedings, Baltimore, MD, 2005, pp. 148–152.
   Google Scholar
• Lin KH, Lin SY, Li MJ. Compression forces and amount of outer coating layer affecting the time-controlled disintegration of the compression-coated tablets prepared by direct compression with micronized ethylcellulose. J Pharm Sci 2001;90:2005–2009.
   PubMed Web of Science ®Google Scholar